Lisata Therapeutics Prepares for Crucial ASCEND Trial Results in 2024
Lisata Therapeutics CEO discusses pivotal year in 2024, Phase 2b ASCEND trial, regulatory milestones, and potential partnership announcements
Readers should care about Lisata Therapeutics' upcoming pivotal year as it could potentially lead to provisional approval applications, regulatory milestones, and early data points in the oncology field. The company's partnerships and developments may have a significant impact on the future of cancer treatment.